Endpoint – Page 37 – Communicable Diseases Research

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

중증 코로나19 환자에서 회복기 혈장 요법의 효과

530

Published on 2020-04-282022-09-06
Journal: Proceedings of the National Academy of Sciences of
[Category] Communicable Disease, COVID-19, SARS,

[키워드] Absorption addition Antibody titers antiviral agent Antiviral agents approved C-reactive protein clinical benefit Clinical outcome clinical outcomes clinical symptom Clinical symptoms convalescent plasma Convalescent plasma therapy coronavirus disease Coronavirus disease 2019 COVID-19 criteria disappearance Donor dose Endpoint enrolled feasibility FIVE global health Health IMPROVE laboratory parameter Laboratory parameters lung lesion lung lesions lymphocyte Lymphocyte count maintain median time Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers Novel coronavirus novel coronavirus disease optimal dose oxyhemoglobin oxyhemoglobin saturation parameter Patient pilot project primary endpoint Radiological examinations randomized trial Seven severe adverse effect severe COVID-19 severe COVID-19 patient Severe patient severe patients Significance significantly supportive care the patient therapy transfused transfusion Treatment Treatment outcome trials undetectable Viral Viral load Viral RNA Viremia
[DOI] 10.1073/pnas.2004168117 PMC 바로가기 [Article Type] 530

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Research Paper

Published on 2020-04-152022-10-28
Journal: Aging (Albany NY)
[Category] COVID-19,

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19

Review article

Published on 2020-04-012022-10-05
Journal: Journal of Virus Eradication
[Category] 신약개발,

[키워드] accounted acute infection acute respiratory syndrome adjusted AEs analysis approved calculate Clinical studies Concentration conducted coronavirus coronavirus disease Course COVID-19 COVID-19 patient database demonstrated dosages dose doses drug drugs EC50 Effects Efficacy Endpoint Evidence for inclusion in vitro India ingredient inhibit initiated margin Metrics nitazoxanide pandemic participant per day pharmacies Placebo Placebo-controlled trials plasma concentration Potential treatment promote raised randomised controlled trial RCT RCTs Replication reported required Research Result review Safe safety profile SARS-CoV-2 searched Serious Adverse Event shown significant difference teratogenic teratogenicity treat Treatment treatments for COVID-19 Trial trials
[DOI] 10.1016/S2055-6640(20)30017-0 [Article Type] Review article

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial

남아프리카 공화국의 유아 및 유아에 대한 비경구 P2-VP8-P[8] 서브유닛 로타바이러스 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조 시험

Articles

Published on 2017-05-052022-09-06
Journal: The Lancet. Infectious Diseases
[Category] Communicable Disease,

[키워드] 95% CI adjusted adverse event adverse events African approach assigned benefit block Block randomisation Cohort computer-generated different dose different doses dose dose-escalation doses double-blind eligible Endpoint enrolled finding FIVE followed by foundation Frequency funding geometric mean geometric mean titre geometric mean titres groups healthy highest HIV-uninfected homologous hospital IgA IgG IgG seroresponse immunogenic immunogenicity Infant Infants injection Injections Laboratory live oral rotavirus vaccines Local Melinda Gate Melinda Gates Mild neutralising antibody neutralising antibody seroresponse neutralising antibody seroresponses nine non-replicating rotavirus vaccine occurred offer oral rotavirus vaccine oral vaccines parent Parenteral parents participant Placebo placebo group placebo-controlled placebo-controlled trial primary immunogenicity randomisation randomised reaction receiving reduced Registered Research rotavirus rotavirus disease rotavirus vaccination rotavirus vaccine Safety safety analysis safety endpoint Serious Adverse Event Serious Adverse Events Serum IgA seroresponse Serum IgA seroresponses Seven severity South South Africa subunit Subunit vaccine systemic reaction systemic reactions the placebo group those receiving placebo Treatment Trial trivalent vaccination Vaccine was done was used
[DOI] 10.1016/S1473-3099(17)30242-6 PMC 바로가기 [Article Type] Articles

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial

CD4 세포 수가 μL당 500개 이상인 HIV 양성인 사람의 중증 세균 감염 위험에 대한 항레트로바이러스 요법의 즉각적인 개시 효과: 무작위 대조 시험의 2차 결과 결과

Articles

Published on 2017-01-052022-09-06
Journal: The Lancet. HIV
[Category] Communicable Disease,

[키워드] 95% CI AIDS allergy analysed Analysis Antiretroviral therapy ART assigned average Bacterial Bacterial infection Bacterial infections bacterial pneumonia Bildung caused CD4 cell Cell composite endpoint Cox proportional hazard Cox proportional hazards regression Cutoff death defined described disorder Effect Endpoint enrolled European explained extrapulmonary tuberculosis Factor finding Follow-up foundation funding hazard ratio Hospital admissions Immediate Increases increases in Infectious disease Infectious diseases median Medical Research Council multivariable analysis network neutrophil neutrophil count Patient Pneumonia randomised controlled trial recruited reduce reduced risk Registered required risk secondary outcome severity subgroup subgroups Trial Tuberculosis univariable analysis
[DOI] 10.1016/S2352-3018(16)30216-8 PMC 바로가기 [Article Type] Articles